# atezolizumab

## name 

阿替利珠单抗, Tecentriq（泰圣奇）

## company

Roche

## MOA 

anti PD-l1

## indication

 urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and hepatocellular carcinoma (HCC).
 
## remarks

 the first PD-L1 inhibitor approved by FDA
